LLY vs. REGN: Eli Lilly vs. Regeneron Pharmaceuticals Stock Comparison

November 11, 2026

How do Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but LLY is classified in Pharmaceuticals while REGN is classified in Biotechnology.

Company profile comparison for Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN)
Profile Item	LLY	REGN
Name	Eli Lilly and Company	Regeneron Pharmaceuticals, Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Biotechnology
GICS Sub-Industry	Pharmaceuticals	Biotechnology
Market Capitalization	1,206.07 billion USD	93.55 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	June 1, 1972	April 2, 1991
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

LLY

REGN

GSPC

Eli Lilly (LLY) vs. Regeneron Pharmaceuticals (REGN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN)
Metric	LLY	REGN
Total Return (1Y)	52.36%	40.87%
Total Return (3Y, Annualized)	34.18%	5.15%
Total Return (5Y, Annualized)	41.08%	8.58%

Risk Profile

Drawdown History

LLY

REGN

GSPC

Eli Lilly (LLY) vs. Regeneron Pharmaceuticals (REGN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN)
Metric	LLY	REGN
Volatility (1Y, Annualized)	35.34%	34.08%
Beta (5Y)	0.40	0.10
Max Drawdown (5Y)	-34.48%	-59.69%
Avg. Volume (3M)	2.52M	772.95K

Risk-Adjusted Performance

Risk-Return Positioning

LLY and REGN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN)
Metric	LLY	REGN
Sharpe Ratio (1Y)	1.36	1.07
Sortino Ratio (1Y)	2.29	1.70

Profitability

ROE (TTM)

Both Eli Lilly (LLY) at 86.02% and Regeneron Pharmaceuticals (REGN) at 14.95% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

86.02%

Max: 109.18%
LLY: 86.02%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.95%

Max: 109.18%
REGN: 14.95%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Eli Lilly (LLY) vs. Regeneron Pharmaceuticals (REGN): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Eli Lilly (LLY) at 31.90% and Regeneron Pharmaceuticals (REGN) at 28.51% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.90%

LLY: 31.90%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.51%

REGN: 28.51%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Eli Lilly (LLY) vs. Regeneron Pharmaceuticals (REGN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Eli Lilly (LLY) at 53.66% and Regeneron Pharmaceuticals (REGN) at 40.46% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

53.66%

Max: 83.12%
LLY: 53.66%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.46%

Max: 83.12%
REGN: 40.46%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Eli Lilly (LLY) vs. Regeneron Pharmaceuticals (REGN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN)
Metric	LLY	REGN
ROE (TTM)	86.02%	14.95%
ROA (TTM)	21.06%	7.59%
Net Margin (TTM)	31.90%	28.51%
Operating Margin (TTM)	53.66%	40.46%
Gross Margin (TTM)	83.63%	46.73%

Growth

Revenue Growth

Both Eli Lilly (LLY) at 44.70% and Regeneron Pharmaceuticals (REGN) at 0.99% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Eli Lilly (LLY) vs. Regeneron Pharmaceuticals (REGN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while Regeneron Pharmaceuticals (REGN) at 8.19% is closer to the peer norm — faster per-share earnings growth for LLY.

Eli Lilly (LLY) vs. Regeneron Pharmaceuticals (REGN): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN)
Metric	LLY	REGN
Revenue Growth (YoY)	44.70%	0.99%
Revenue Growth (3Y CAGR)	31.69%	5.62%
EPS Growth (YoY)	95.99%	8.19%
EPS Growth (3Y CAGR)	51.71%	2.77%

Financial Strength

Current Ratio (MRQ)

Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while Eli Lilly (LLY) at 1.39 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for LLY.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.39

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
LLY: 1.39
Min: 0.10

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.35

Max: 25.13
Q3: 12.13
Median: 5.52
REGN: 3.35
Q1: 2.47
Min: 0.10

Eli Lilly (LLY) vs. Regeneron Pharmaceuticals (REGN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Regeneron Pharmaceuticals (REGN) at 0.08 carries an industry-typical debt-to-equity mix, while Eli Lilly (LLY) at 1.23 uses more debt funding than most peers.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.23

Max: 1.42
LLY: 1.23
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.08

Max: 1.42
Q3: 0.65
Median: 0.15
REGN: 0.08
Q1: 0.02
Min: 0.00

Eli Lilly (LLY) vs. Regeneron Pharmaceuticals (REGN): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN)
Metric	LLY	REGN
Current Ratio (MRQ)	1.39	3.35
Debt / Equity (MRQ)	1.23	0.08
Net Debt / EBITDA	0.96	-1.17

Dividends

Dividend Yield (TTM)

Both Eli Lilly (LLY) at 0.49% and Regeneron Pharmaceuticals (REGN) at 0.41% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.49%

LLY: 0.49%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41%

REGN: 0.41%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Eli Lilly (LLY) vs. Regeneron Pharmaceuticals (REGN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Eli Lilly (LLY) at 21.71% and Regeneron Pharmaceuticals (REGN) at 8.18% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.71%

LLY: 21.71%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.18%

REGN: 8.18%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Eli Lilly (LLY) vs. Regeneron Pharmaceuticals (REGN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN)
Metric	LLY	REGN
Dividend Yield (TTM)	0.49%	0.41%
Dividend Payout Ratio (TTM)	21.71%	8.18%

Valuation

P/E Ratio (TTM)

Regeneron Pharmaceuticals (REGN) at 19.99 is near its industry’s usual P/E ratio, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — LLY needs stronger growth or earnings quality to justify the premium.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.95

Max: 85.34
LLY: 43.95
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.99

Max: 85.34
Q3: 43.46
Median: 26.69
REGN: 19.99
Q1: 13.30
Min: 0.07

Eli Lilly (LLY) vs. Regeneron Pharmaceuticals (REGN): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Eli Lilly (LLY) at 13.95 and Regeneron Pharmaceuticals (REGN) at 5.54 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.95

Max: 58.18
Q3: 25.77
LLY: 13.95
Median: 7.30
Q1: 3.01
Min: 0.01

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.54

Max: 58.18
Q3: 25.77
Median: 7.30
REGN: 5.54
Q1: 3.01
Min: 0.01

Eli Lilly (LLY) vs. Regeneron Pharmaceuticals (REGN): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Regeneron Pharmaceuticals (REGN) at 2.71 sits near its industry’s typical P/B ratio, while Eli Lilly (LLY) at 29.96 prices above its benchmark range — LLY looks rich relative to book.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.96

LLY: 29.96
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.71

Max: 13.53
Q3: 6.54
Median: 3.25
REGN: 2.71
Q1: 1.69
Min: -5.59

Eli Lilly (LLY) vs. Regeneron Pharmaceuticals (REGN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN)
Metric	LLY	REGN
P/E Ratio (TTM)	43.95	19.99
P/S Ratio (TTM)	13.95	5.54
P/B Ratio (MRQ)	29.96	2.71
Free Cash Flow Yield (TTM)	0.77%	2.76%